HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer

After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect Welireg surprisingly failed to ignite hope as a first-line treatment.

By FiercePharma · Apr 22, 2026 · via FiercePharma
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer

Image: FiercePharma

Tags
pipelineformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises
PipelineFierceBiotech ↗
AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, R…
Apr 22, 2026
FDA approves once-daily HIV pill from Merck
PipelineEndpoints News ↗
FDA approves once-daily HIV pill from Merck
A new HIV treatment will soon come to market, and it will spearhead Merck’s attempt to be one of the leading d…
Apr 21, 2026
STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem
PipelineSTAT News ↗
STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem
At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myelo…
Apr 20, 2026